Physician profile
Patrick Wong
NPI 1508250705
$3,490.45
in general payments reported to CMS, 2019-2025
19 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $154 · 2021: $254 · 2022: $610 · 2023: $693 · 2024: $868 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288 · Education: $65.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.83 |
| Education | $65.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,019.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $444.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $418.87 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $372.96 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $359.85 | 2022-2025 | |
| Exact Sciences Corporation | $199.61 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $113.85 | 2020-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $107.53 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.50 | 2023-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $78.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.54 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $65.95 | 2023-2024 | Rexulti |
| Abbvie INC. | $29.24 | 2021 | |
| Genentech USA, INC. | $26.81 | 2020-2022 | |
| Abbott Laboratories | $16.56 | 2024 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.92 | 2024 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $15.83 | 2024 | Isturisa, Signifor Lar |
| Allergan, INC. | $14.94 | 2020 | |
| Merck Sharp & Dohme LLC | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.